These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22346438)

  • 41. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.
    Molinari G; Guzmán CA; Pesce A; Schito GC
    J Antimicrob Chemother; 1993 May; 31(5):681-8. PubMed ID: 8392997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of macrolides on proinflammatory epitopes on endothelial cells in vitro.
    Millrose M; Kruse M; Flick B; Stahlmann R
    Arch Toxicol; 2009 May; 83(5):469-76. PubMed ID: 19052724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.
    Wright AJ; Gomes T; Mamdani MM; Horn JR; Juurlink DN
    CMAJ; 2011 Feb; 183(3):303-7. PubMed ID: 21242274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of azithromycin and clarithromycin in clinical practice.
    Goldman MP; Longworth DL
    Cleve Clin J Med; 1993; 60(5):359-64. PubMed ID: 8403355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
    Renaudin H; Bébéar C
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response.
    Tateda K; Ishii Y; Matsumoto T; Kobayashi T; Miyazaki S; Yamaguchi K
    J Infect Chemother; 2000 Mar; 6(1):1-7. PubMed ID: 11810524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.
    Tateda K; Ishii Y; Matsumoto T; Furuya N; Nagashima M; Matsunaga T; Ohno A; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2271-5. PubMed ID: 8891128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The newer macrolides: azithromycin and clarithromycin.
    Zuckerman JM
    Infect Dis Clin North Am; 2000 Jun; 14(2):449-62, x. PubMed ID: 10829265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
    Felmingham D; Robbins MJ; Sanghrajka M; Leakey A; Ridgway GL
    Drugs Exp Clin Res; 1991; 17(2):91-9. PubMed ID: 1650694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [LONG TERM TREATMENT WITH MACROLIDES IN CHRONIC LUNG DISEASES].
    Shteinberg M; Schneer S; Lavon O; Adir Y
    Harefuah; 2016 Sep; 155(9):567-571. PubMed ID: 28530085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.
    Peters DH; Friedel HA; McTavish D
    Drugs; 1992 Nov; 44(5):750-99. PubMed ID: 1280567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V; Thorburn CE; Knott SJ; Woodnutt G
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection.
    Berg-Candolfi M; Candolfi E
    Int J Parasitol; 1996 Nov; 26(11):1321-3. PubMed ID: 9024879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.
    Malhotra-Kumar S; Lammens C; Coenen S; Van Herck K; Goossens H
    Lancet; 2007 Feb; 369(9560):482-90. PubMed ID: 17292768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microbiologic activity of the newer macrolide antibiotics.
    McCracken GH
    Pediatr Infect Dis J; 1997 Apr; 16(4):432-7. PubMed ID: 9109155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-inflammatory activity of macrolide antibiotics.
    Ianaro A; Ialenti A; Maffia P; Sautebin L; Rombolà L; Carnuccio R; Iuvone T; D'Acquisto F; Di Rosa M
    J Pharmacol Exp Ther; 2000 Jan; 292(1):156-63. PubMed ID: 10604943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes.
    Galvidis I; Lapa G; Burkin M
    Anal Biochem; 2015 Jan; 468():75-82. PubMed ID: 25256165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.